Clinical Trial Update: Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

View source ↗

Summary

Clinical trial evaluating the antitumor immune response after concurrent chemoradiotherapy and immunotherapy in non-resectable stage III non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Fundación GECP | Conditions: Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation | Status: RECRUITING